By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Catalyst Biosciences, Inc. 

260 Littlefield Avenue

South San Francisco  California  94080  U.S.A.
Phone: 650-871-0761 Fax: n/a



Company News
Catalyst Biosciences Reports Second Quarter 2017 Financial Results And Provides Subcutaneous (SQ) Hemophilia Program Update 8/3/2017 1:22:29 PM
Financial Milestone Achieved In Catalyst Biosciences' Subcutaneous Factor IX Program 7/6/2017 11:06:08 AM
Catalyst Biosciences’ Factor IX Granted Orphan Drug Designation In Europe 6/28/2017 8:59:02 AM
Catalyst Biosciences Announces Achievement Of Stable Normal Factor IX Blood Levels In A Preclinical Subcutaneous Dosing Model 6/26/2017 11:21:51 AM
Catalyst Biosciences And ISU Abxis Complete Dosing Of First Patient Cohort In Hemophilia B Clinical Trial 6/14/2017 12:08:36 PM
Catalyst Biosciences Announces Presentations On Its Next-Generation Subcutaneous Hemophilia Product Candidates At The 2017 International Society On Thrombosis And Haemostasis (ISTH) Meeting 6/8/2017 10:42:58 AM
Catalyst Biosciences’ Factor IX Recommended For Orphan Drug Designation In Europe 5/31/2017 10:18:58 AM
Catalyst Biosciences Reports First Quarter 2017 Financial Results and Provides Corporate Update 5/11/2017 9:10:14 AM
Catalyst Biosciences Announces Closing Of A $20.7 Million Underwritten Public Offering And Full Exercise Of Over-Allotment Option 4/13/2017 9:57:22 AM
Key Milestone Reached In Catalyst Biosciences’s Subcutaneous Factor IX Program 4/11/2017 9:44:57 AM